Skip to main content
. 2023 Oct 9;83(22):3796–3812. doi: 10.1158/0008-5472.CAN-23-0385

Figure 6.

Figure 6. Mutational signature patterns across the cohort. A, Stacked line chart of mutational signature contribution by total number of mutations attributed to each signature. Colors represent the different signatures. B, Stacked bar chart of the relative contribution of HRD-related SBS3 (green) and cisplatin (blue) signature in metastatic and relapse samples. C, Stacked bar chart of the relative contribution of HRD (green), clock-like (pink), ROS damage (red), late replication errors (beige), somatic hypermutation (orange), and APOBEC (teal) in primary site samples. D, Stacked bar chart of the probability that driver gene SNVs were attributed to a mutational signature. Pretreatment samples from patients with driver SNVs were included and the primary resection sample from OSCE9 because no pretreatment sample was available. Colors represent the different signatures.

Mutational signature patterns across the cohort. A, Stacked line chart of mutational signature contribution by total number of mutations attributed to each signature. Colors represent the different signatures. B, Stacked bar chart of the relative contribution of HRD-related SBS3 (green) and cisplatin (blue) signature in metastatic and relapse samples. C, Stacked bar chart of the relative contribution of HRD (green), clock-like (pink), ROS damage (red), late replication errors (beige), somatic hypermutation (orange), and APOBEC (teal) in primary site samples. D, Stacked bar chart of the probability that driver gene SNVs were attributed to a mutational signature. Pretreatment samples from patients with driver SNVs were included and the primary resection sample from OSCE9 because no pretreatment sample was available. Colors represent the different signatures.